Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs

European Journal of Clinical Investigation
F BriandKhadija Ouguerram

Abstract

The mechanisms involved in the decline of high-density lipoprotein (HDL) levels at a higher dose of atorvastatin have not yet been elucidated. We investigated the effects of atorvastatin on HDL-apolipoprotein (apo) A-I metabolism in dogs, a species lacking cholesteryl ester transfer protein activity. Seven ovariectomized normolipidaemic female Beagle dogs underwent a primed constant infusion of [5,5,5-(2)H(3)] leucine to determine HDL-apo A-I kinetics before and after atorvastatin treatment (5 mg kg(-1) d(-1) for 6 weeks). Plasma lipoprotein profiles, activity of HDL-modifying enzymes involved in reverse cholesterol transport and hepatic scavenger receptor class B type I (SR-BI) expression were also studied. Atorvastatin treatment decreased HDL-cholesterol levels (3.56 +/- 0.24 vs. 2.64 +/- 0.15 mmol L(-1), P < 0.05). HDL-triglycerides were not affected. HDL-phospholipids levels were decreased (4.28 +/- 0.13 vs. 3.29 +/- 0.13 mmol L(-1), P < 0.05), as well as phospholipids transfer protein (PLTP) activity (0.83 +/- 0.05 vs. 0.60 +/- 0.05 pmol microL(-1) min(-1), P < 0.05). Activity of lecithin: cholesterol acyl transferase (LCAT), hepatic lipase (HL) and SR-BI expression did not change. HDL-apo A-I absolute production rate (APR...Continue Reading

References

Aug 1, 1989·The American Journal of Physiology·M E BlankD F Diedrich
Jan 1, 1994·Research in Veterinary Science·L G DownsC H Bolton
Apr 20, 1999·The Journal of Clinical Investigation·B LamarcheG F Lewis
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·T AraiA R Tall
Jan 11, 2000·QJM : Monthly Journal of the Association of Physicians·A S WierzbickiM A Crook
Jun 8, 2001·The Journal of Clinical Investigation·G MartinB Staels
Sep 18, 2002·Journal of Lipid Research·Jeffrey S CohnJean Davignon
May 22, 2003·Metabolism: Clinical and Experimental·Edwige BailhacheKhadija Ouguerram
Sep 16, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Alan R Tall, Florent Lalanne
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
Jan 24, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Ronald W ClarkMark J Bamberger
Apr 9, 2004·The New England Journal of Medicine·Margaret E BrousseauDaniel J Rader
Aug 18, 2004·Circulation·Carl J Vaughan, Antonio M Gotto
Aug 25, 2004·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·Khadija OuguerramThierry Magot
Oct 12, 2004·Biochemical and Biophysical Research Communications·Takashi MaejimaY Saito
Mar 2, 2005·Nature Reviews. Drug Discovery·Patrick Linsel-Nitschke, Alan R Tall
May 14, 2005·Current Opinion in Lipidology·Stephen J NichollsPhilip J Barter
Jul 15, 2005·The Journal of Pharmacology and Experimental Therapeutics·K Bach-NgohouJ M Bard

❮ Previous
Next ❯

Citations

Jun 28, 2011·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A D Dergunov
Oct 13, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Baoying YuanHong Feng
Jun 2, 2010·Journal of Atherosclerosis and Thrombosis·Shizuya YamashitaMakoto Nishida
Nov 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Takao KimuraFumikazu Okajima

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.